News
ENZ
--
0.00%
--
ENZO BIOCHEM ANNOUNCES APPOINTMENT OF IAN B. WALTERS, MD, TO ITS BOARD OF DIRECTORS
NEW YORK, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD, has been appointed to the Company’s Board of Directors effective immediately.    Dr. Walters is an experienced entrepreneur and drug developer with leadership in the development of over 30 drugs in multiple therapeutic areas involving diverse technologies, leading to five new oncology drug approvals. His previous positions include Executive Director of Global Oncology Clinical Research and Business Development for Bristol-Myers Squibb, and Medical Director at Millennium Pharmaceuticals. Dr. Walters currently is CEO and Director of Portage Biotech, a publicly traded clinical stage biopharmaceutical company developing an innovative portfolio of immuno-oncology assets. He is also founder of seven of Portage’s portfolio companies.Dr. Walters holds an MBA from the Wharton School of the University of Pennsylvania. He received his MD at the Albert Einstein College of Medicine and completed doctoral training in experimental medicine at The Rockefeller University.  Dr. Walters has been the lead author or contributor to approximately 60 journal publications.“Dr. Walters brings over two decades of diverse experience in drug development and business strategy, including both founding and executive level positions at several life sciences companies,” said Dr. Elazar Rabbani, Ph.D., Enzo’s Chairman and Chief Executive Officer.  “As a physician, scientist and entrepreneur, his deep expertise spans clinical development, regulatory affairs, and strategic planning.  At a time when we have announced promising growth and continued momentum going into 2021, Dr. Walters will play an integral role in identifying new ways Enzo’s offerings can effectively support companion diagnostics, early drug discovery, and liquid biopsy techniques.” “Enzo continues to demonstrate its role as an innovative leader through its rapid response to the COVID-19 pandemic and continued implementation of cost effective, adaptive technologies to address key challenges in the clinical diagnostics industry,” said Dr. Walters.  “I am eager to work together with the other members of the board and Enzo’s management team to assure its future success and target new opportunities for growth.” About Enzo BiochemEnzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. For additional information please visit: http://www.enzo.com/ Forward-Looking StatementsExcept for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release. Contacts:David Bench, CFO Enzo Biochem, Inc. 212-583-0100 dbench@enzo.comMedia: Marisa Monte            Berry & Company Public Relations 212-253-8881 mmonte@berrypr.comInvestors:Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.comSteve Anreder Anreder & Company 212-532-3232 Steven.anreder@anreder.com
GlobeNewswire · 1d ago
Harbert Discovery Fund Issues Letter to Enzo Biochem Board of Directors
BIRMINGHAM, Ala., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Elazar Rabbani, Dov Perlysky, Rebecca Fischer,We are writing to demand Elazar Rabbani immediately resign as CEO and from the Board of Directors (the “Board”) of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”). Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”) currently own approximately 11.74% of the outstanding shares of Enzo, making us the Company’s largest shareholder.As you will recall, despite your attempts to further entrench the Board during the last proxy campaign, shareholders overwhelmingly voted to elect Fabian Blank and Pete Clemens as directors on February 25, 2020 largely because of their desire to see change at Enzo. Shareholders voted for Pete and Fabian because of the Company’s long history of underperformance, significant share price declines, and disillusionment with a management team that clearly places its own interests ahead of shareholders. It is no surprise that the fundamental results began to improve after Pete and Fabian joined the Board. Based on the timing and unexpected nature of Fabian and Pete’s resignations, it appears that Chairman and CEO Rabbani has created such an extremely hostile environment that Pete and Fabian found their position untenable as minority members in opposition to Mr. Rabbani’s continued mismanagement.Upon disclosing the resignations of Pete and Fabian, Enzo announced that preliminary revenue for fiscal Q1 exceeded $27 million, the highest revenue quarter the Company has achieved in years. Enzo is clearly benefitting from the increased demand for COVID-19 testing, and we expect this dynamic to continue. It speaks volumes that despite the positive revenue news, shares traded down around 2.5%.This trading behavior clearly reflects shareholders’ fundamental distrust and frustration with management and the remaining directors. This decline extended the shares year-to-date declines to -25%. Conversely, other public companies benefitting from COVID-19 testing have generated outsized shareholder returns in 2020. Opko, LabCorp, and Quest Diagnostics generated 2020 year-to-date shareholder returns of 169%, 21%, and 19%, respectively. For Enzo, 2020 is a continuation of a long-history of dramatic underperformance.  Total Shareholder Return  YTD1 Year3 Year5 Year10 Year20 Year LabCorp21.0%19.4%36.2%65.9%151.7%448.8% Quest18.6%21.5%41.9%101.7%195.5%490.9% Opko169.4%165.8%(16.6%)(63.2%)37.6%(50.2%) Average69.7%68.9%20.5%34.8%128.2%296.5%         Enzo(24.7%)(31.7%)(78.5%)(56.0%)(52.7%)(93.7%) Note: Data per Bloomberg as of November 17, 2020. Elazar Rabbani has controlled and mismanaged Enzo for over 40 years. He has consistently paid himself bonuses in spite of negative shareholder returns, he has overseen numerous conflicts of interest, and he has failed to create shareholder value. We have spoken with numerous former employees and not a single one has anything positive to say about his leadership or character. There is a consistent theme that he cares more about maintaining control of the Company than supporting his employees, or creating value for shareholders. Enough is enough. It is time for the remaining “independent” directors to demand Elazar’s immediate resignation. Upon his resignation, the Company should immediately pursue a sale. M&A multiples are increasing, based on the current demand for lab assets. We believe at a minimum the Company could realize 2x revenues in a sale. Based on recently announced run-rate Q1 fiscal 2021 revenue, that would result in $5.51 per share, or 178% upside from current levels. This is clearly a better option for shareholders than continuing with the current status quo, where even positive fundamental results send the stock down as a result of the extreme and justified distrust of Elazar Rabbani. It is worth noting that the Company has not updated shareholders on the status of its engagement with Lazard since January of 2020. We believe they deserve an update.Investors are left to ponder what independent directors Perlysky and Fischer stand to benefit from Elazar’s continued entrenchment. Evidently, they have placed their own interest in furthering Elazar’s unscrupulous behavior and self-dealing ways ahead of thousands of individual and institutional investors.We hope that recently added director Mary Tagliaferri is truly independent and capable of an unbiased assessment of Enzo’s management. Time will tell.Should directors Perlysky and Fischer refuse to recognize the mandate for change from shareholders and exhibit a preference for systemic cronyism, then at a minimum we request that the Board hire an independent, reputable law firm to investigate Elazar’s various conflicts.Shareholders deserve better. You can do better. It is a shame and blight on your and Enzo’s reputations that you won’t.Sincerely,Harbert Discovery Fund, LP    Harbert Discovery Co-Investment Fund I, LP    Kenan Lucas, Managing Director and Portfolio Manager of Harbert Discovery Fund GP, LLC and Harbert Discovery Co-        Investment Fund I GP, LLCImportant DisclosureTHIS STATEMENT CONTAINS OUR CURRENT VIEWS ON THE VALUE OF SECURITIES OF ENZO BIOCHEM, INC. (“ENZO”). OUR VIEWS ARE BASED ON OUR ANALYSIS OF PUBLICLY AVAILABLE INFORMATION AND ASSUMPTIONS WE BELIEVE TO BE REASONABLE. THERE CAN BE NO ASSURANCE THAT THE INFORMATION WE CONSIDERED IS ACCURATE OR COMPLETE, NOR CAN THERE BE ANY ASSURANCE THAT OUR ASSUMPTIONS ARE CORRECT. WE DO NOT RECOMMEND OR ADVISE, NOR DO WE INTEND TO RECOMMEND OR ADVISE, ANY PERSON TO PURCHASE OR SELL SECURITIES AND NO ONE SHOULD RELY ON THIS STATEMENT OR ANY ASPECT OF THIS STATEMENT TO PURCHASE OR SELL SECURITIES OR CONSIDER PURCHASING OR SELLING SECURITIES. THIS STATEMENT DOES NOT PURPORT TO BE, NOR SHOULD IT BE READ, AS AN EXPRESSION OF ANY OPINION OR PREDICTION AS TO THE PRICE AT WHICH ENZO’S SECURITIES MAY TRADE AT ANY TIME. AS NOTED, THIS STATEMENT EXPRESSES OUR CURRENT VIEWS ON ENZO. OUR VIEWS AND OUR HOLDINGS COULD CHANGE AT ANY TIME WITHOUT NOTICE AND WE MAKE NO COMMITMENT TO UPDATE THIS STATEMENT IN THE EVENT OUR VIEWS OR HOLDINGS CHANGE. INVESTORS SHOULD MAKE THEIR OWN DECISIONS REGARDING ENZO AND ITS PROSPECTS WITHOUT RELYING ON, OR EVEN CONSIDERING, ANY OF THE INFORMATION CONTAINED IN THIS STATEMENT.About Harbert Discovery Fund (“HDF”)HDF invests in a concentrated portfolio of publicly traded small capitalization companies in the US and Canada. We perform significant due diligence on each portfolio company prior to investing. In addition to researching all publicly available information and meeting with management, our diligence includes substantial primary research with industry experts, consultants, bankers, customers and competitors. We often spend months or years researching ideas before making an investment decision and we only invest in companies that we believe are significantly undervalued, and where there is the potential for change to enhance or accelerate value creation. In an effort to unlock this potential value, we seek to work directly with the boards and management teams of our portfolio companies privately and collaboratively, engaging with them on a range of factors including governance, board composition, corporate strategy, capital allocation, strategic alternatives and operations. We have effected positive, fundamental changes at our current and past investments through this behind-the-scenes, constructive approach. HDF currently has board representation at three of our portfolio companies. In each case, changes to the board were agreed upon privately and it is our strong preference in every investment to avoid the unnecessary distractions and costs of a public proxy campaign.About Harbert Management Corporation (“HMC”)HMC is an alternative asset management firm with approximately $7.4 billion in regulatory assets under management as of October 31, 2020. HMC currently sponsors eight distinct investment strategies with dedicated investment teams. Additional information about HMC can be found at www.harbert.net.Contact: HMC Investor Relations Telephone: 205.987.5500 E-mail: irelations@harbert.net
GlobeNewswire · 11/18 18:00
ENZO BIOCHEM ANNOUNCES APPOINTMENT OF MARY TAGLIAFERRI, MD, TO ITS BOARD OF DIRECTORS
NEW YORK, NY, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, MD, has been appointed to the company’s Board of Directors effective immediately.    “In 2020, Enzo reported significant progress in advancing our business plan to achieve profitability including strong results in many areas of our operations that position us for new levels of growth and momentum in 2021,” said Dr. Elazar Rabbani, Ph.D., Enzo’s Chairman and Chief Executive Officer.  “Dr. Tagliaferri is a highly-respected industry leader with broad global experience in a range of operational areas including business development, clinical research and development, world-wide regulatory matters and medical affairs.  She will play a central role in our continued success and future growth at Enzo.”Dr. Tagliaferri is currently Executive Clinical Fellow and Senior Vice President and she was previously Chief Medical Officer at Nektar Therapeutics, a leading research-based biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need including treatments for cancer and auto-immune disease.  Previously, she served as Chief Medical Officer and Chief Regulatory Officer for Kanglaite-USA and was Co-Founder, President and Board Member of Bionovo, Inc.  She earned her Bachelor of Science degree at Cornell University and her medical degree at the University of California, San Francisco. Dr. Tagliaferri was named to the Women who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019 and was recognized as Woman of the Year, 2012, by the State of California, Assembly District 14.  She has been lead author or contributor to approximately 70 journal publications.“I am very pleased to be joining the Enzo Board of Directors at a time that presents so many important opportunities for the company to continue to show innovation and leadership in response to the COVID-19 pandemic and other emerging health challenges,” said Dr. Tagliaferri.  “I look forward to working closely with the members of the board and the Enzo leadership team to maximize the full range of business opportunities the company is targeting in the years ahead.”“In recent months, Enzo has announced many significant advances in our business strategy, including receipt of FDA Emergency Use Authorization for our GenFlex™ platform for COVID-19 testing, expansion of our Farmingdale, New York facility, launch of our direct-to-consumer testing service, and the recent introduction of our microplate reader for use with our ELISA and assay kits,” Dr. Rabbani added.   “Dr. Tagliaferri’s outstanding experience will be an important resource for us to continue this momentum and identify and target a wide range of new strategic opportunities to expand our operations and address new areas of unmet need.”About Enzo Biochem   Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.Forward-Looking StatementsExcept for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release. Contact:For Enzo Biochem, Inc.David Bench, CFO 212-583-0100 dbench@enzo.comMedia:Marisa Monte            Berry & Company Public Relations 212-253-8881 mmonte@berrypr.comInvestors:Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.comSteve Anreder Anreder & Company 212-532-3232 Steven.anreder@anreder.com
GlobeNewswire · 11/18 13:05
ENZO PROVIDES CORPORATE BUSINESS UPDATE
NEW YORK, NY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that the company estimates revenue to meet or exceed $27 million, representing sequential growth of at least 40%, for the quarter ended October 31, 2020.  Enzo Biochem, Inc. also announced today that Fabian Blank and Peter Clemens have resigned from the company board of directors, effective immediately. Both board members were originally nominated by Harbert Discovery Fund, LP (Harbert), an investor in Enzo. The Nominating Committee for Enzo has already identified experienced Board candidates to fill the vacant seats and expects to announce their appointment in the near future.“Enzo is projecting significant progress in our strategy to streamline operations to achieve profitability in fiscal 2021, which represents the culmination of several years of planning and execution,” said Dr. Elazar Rabbani, Ph.D., Enzo’s Chairman and Chief Executive Officer. “With our board and management team advancing our business strategy, we look to continue building new levels of momentum in this process in the months ahead.” In 2020, Enzo announced several developments designed to advance its business operations, including receipt of FDA Emergency Use Authorization for the company’s GenFlex™ platform for COVID-19 testing, significant expansion of the Farmingdale, New York facility to meet rapidly expanding commercial demand for testing services, expansion of its School and Institutional Testing (SIT) program to support efforts by organizations to re-open safely during the COVID-19 pandemic, and launch of our direct-to-consumer testing service.  Most recently, the company launched its microplate reader for use with its ELISA and assay kits to simplify laboratory workflow.“2020 has been a year of many significant accomplishments for Enzo that have strengthened our business operations and commercial opportunities, and we are pleased to see the results of these actions reflected in our revenue growth and expansion of our customer focus,” continued Dr. Rabbani.  “We have expanded our opportunities for success in all of our business sectors, including Molecular Diagnostics, Immunoassay, Immunohistochemistry, and Cytology, and the company is well positioned to maximize our potential for growth, investment, joint ventures, and partnerships in 2021.”  About Enzo Biochem   Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.Forward-Looking StatementsExcept for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release. Contact:For Enzo Biochem, Inc.David Bench, CFO 212-583-0100 dbench@enzo.comMedia: Marisa Monte         Berry & Company Public Relations 212-253-8881 mmonte@berrypr.comInvestors:Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.comSteve Anreder Anreder & Company 212-532-3232 Steven.anreder@anreder.com
GlobeNewswire · 11/17 13:00
Enzo Biochem Launches Microplate Reader For Use With Its Elisa And Assay Kits
- Powerful and precise compact instrument enables Enzo to offer a  complete solution to advance drug discovery - Microplate reader can be retrofitted for point-of-care clinical testing at urgent care facilities,
Powerful and precise compact instrument enables Enzo to offer a  complete solution to advance drug discovery - Microplate reader can be retrofitted for point-of-care clinical testing at urgent care facilities, · 11/05 13:13
ENZO LAUNCHES PORTABLE MICROPLATE READER FOR USE WITH ITS ELISA AND ASSAY KITS TO SIMPLIFY LABORATORY WORKFLOW
\- Powerful and precise compact instrument enables Enzo to offer a  complete solution to advance drug discovery \- Microplate reader can be retrofitted for point-of-care clinical testing at urgent care facilities, hospitals or physicians’ officesNEW YORK, NY, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today the commercial launch of a small portable microplate reader for use with the company’s immunoassays and, ultimately, molecular diagnostics, providing new opportunities in point-of-care medicine. This affordable device enables Enzo to offer a complete solution to academic, CRO, and industrial customers.Enzo is the provider of over 17,000 ELISA (enzyme-linked immunosorbent assay) and assay kits, including hundreds of highly sensitive ELISAs it manufactures. The advanced design and technology of Enzo’s compact microplate reader makes it possible to deliver precise and accurate results. Together with Enzo’s proprietary software, the device is an option for a wide variety of applications based on the miniaturization of Enzo’s assays. These tests include metabolites, hormones (e.g. pregnancy), proteins (e.g. inflammatory cytokines) and protein characterization. With support from an instrument manufacturing company, the Enzo portable reader enables lab work to be executed outside of traditional research facilities (that rely on shared instrumentation). Now, researchers and lab professionals can have a dedicated, personal device to fit their space and needs with convenience and accessibility not previously available. The handheld instrument is about one-tenth the size of the average benchtop plate reader, allowing it to fit into any laboratory setting and saving bench space while providing new levels of flexibility and portability that can be extended to point-of-care facilities to allow physicians to provide molecular testing including assays for viral detection and sexually transmitted diseases. The compact solid-state technology enables utilization of this instrument in new locations. With this technology, point-of-care testing can move from centralized, complex clinical labs closer to patient care. It simplifies testing procedures and opens up the opportunity to shift testing out of the hands of licensed medical technicians to healthcare professionals operating nearer to patients or, in some instances, even to patients themselves. “Access to point-of-care testing continues to grow as technological advances in clinical diagnostic testing drive miniaturization of complex devices. Now, just as computers moved from mainframes to powerful, portable handheld devices, the same is happening within the clinical diagnostic testing industry. This reduced complexity provides high quality and precise testing capabilities to be available to a broader range of healthcare professionals involved in patient management whether they are sitting at an urgent care facility, a doctor’s office or hospital bedside,” said Kara Cannon, Chief Commercial Officer of Enzo.  “The point-of-care testing market, currently valued at over $18B globally, has the potential to aggressively expand to many testing needs that are now not widely available at point-of-care, including a significant portion of the $15B immunoassay testing market,” added Ms. Cannon. “Common clinical immunoassay tests, such as vitamin D testing and inflammation analysis, currently are performed regularly in the clinical central testing lab by licensed medical technologists using large, complex instrumentation. Unlike lateral flow assays, this small yet powerful system does not sacrifice sensitivity for convenience and allows for multi-assay capabilities.” “Enzo’s corporate vision addresses new opportunities for expansion and growth within both products and services,” added Ms. Cannon. “We are serving markets including laboratories, point-of-care, and direct-to-consumer. This market launch is an important step in extending our offerings beyond the central laboratory, enabling physicians to provide clinical testing at their office, urgent care facility, or other treatment center.” In the future, Enzo anticipates launching isothermal testing on this platform, enabling constant temperature and eliminating the need for a thermal cycler. To learn more about Enzo’s plate readers and the full range of Enzo assays, researchers can visit www.enzolifesciences.com/absorbance96. About Enzo Biochem   Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.Forward-Looking StatementsExcept for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release. Contact:For Enzo Biochem, Inc.David Bench, CFO 212-583-0100 dbench@enzo.comMedia: Marisa Monte        Berry & Company Public Relations 212-253-8881 mmonte@berrypr.comInvestors:Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.comSteve Anreder Anreder & Company 212-532-3232 Steven.anreder@anreder.com
GlobeNewswire · 11/05 13:00
Enzo Biochem Launches GoTestMeNow Online Platform For Consumers To Directly Order Coronavirus Laboratory Tests
ENZO BIOCHEM LAUNCHES GOTESTMENOW™ ONLINE PLATFORM FOR CONSUMERS TO DIRECTLY ORDER COVID-19 LABORATORY TESTS Direct-to-Consumer service will initially offer access to COVID-19 molecular and antibody testing
Benzinga · 10/27 12:01
ENZO BIOCHEM LAUNCHES GOTESTMENOW™ ONLINE PLATFORM FOR CONSUMERS TO DIRECTLY ORDER COVID-19 LABORATORY TESTS
Direct-to-Consumer service will initially offer access to COVID-19 molecular and antibody testing and will expand to include other testing in the future Enzo’s first-ever DTC testing service allows consumers to access physician-authorized testing and receive results through secure online portalNEW YORK, NY, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it has launched GoTestMeNow™, a new online platform that enables consumers to directly order physician-authorized laboratory testing.  GoTestMeNow™ can be used to access necessary medical tests without the need for a doctor’s office visit.  Specimen collection and testing is accomplished through a network of patient service centers in the New York/New Jersey metro area.  Consumers can obtain results through a secure online portal. The GoTestMeNow™ direct-to-consumer laboratory testing capability will initially support access to COVID-19 molecular and antibody testing, and the platform will be expanded to offer access to a broad range of additional tests in the near future.“One of the frustrating issues for individuals concerned about their risk of COVID-19 infection is the requirement that they must visit a doctor’s office for authorization to be tested.  This issue is keeping thousands of people from getting tested each week,” said Barry Weiner, president of Enzo.  “Enzo’s GoTestMeNow™ platform enables people to access testing more easily and faster with the oversight of a licensed physician but without the need to visit the doctor’s office.  As we work to address the most critical needs in laboratory testing by bringing easier access to COVID-19 testing, we are planning to expand the platform for consumers to also access a broad range of additional testing services and home testing kits, including testing for sexually transmitted diseases, many of which require rapid diagnosis and treatment to avoid risk of long-term health problems.”The GoTestMeNow™ platform is designed to offer the highest levels of speed and convenience in helping consumers access laboratory testing services: * Individuals order the desired test online. * A licensed physician providing clinical oversight for GoTestMeNow™ services will be alerted for prompt review and authorization of the test. * The platform facilitates all needs related to payment, including insurance coverage. * Consumers can visit the testing location that is most convenient for their needs. * Results are available to patients through a secure online portal. * A FAQ section as well as a phone and email contact are available for patients to access should they have any questions at www.gotestmenow.com.“The GoTestMeNow platform brings a new focus on public health to laboratory testing by making it easier to access high-quality testing services locally,” added Mr. Weiner. “Enzo’s laboratory has the infrastructure necessary to locally and rapidly support all testing needs with complete solutions in molecular diagnostics, immunoassays, immunohistochemistry and cytology.”To access COVID-19 testing services, consumers can visit Enzo’s direct-to-consumer platform at www.gotestmenow.com. Enzo’s diagnostic and laboratory services are backed by extensive data and research.  Details about the company’s AMPIPROBE® SARS-CoV-2 Test System and the full range of COVID-19 products and services are available at https://www.enzo.com/coronavirus.About Enzo Biochem   Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.Forward-Looking StatementsExcept for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.Contact:For Enzo Biochem, Inc.David Bench, CFO 212-583-0100 dbench@enzo.comMedia: Marisa Monte Berry & Company Public Relations 212-253-8881 mmonte@berrypr.comInvestors:Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.comSteve Anreder Anreder & Company 212-532-3232 Steven.anreder@anreder.com
GlobeNewswire · 10/27 12:00
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Allscripts Healthcare Solutions Shares Jump
Toward the end of trading Wednesday, the Dow traded down 0.45% to 28550.31 while the NASDAQ fell 0.75% to 11775.45. The S&P also fell, dropping 0.56% to 3,492.39.
Benzinga · 10/14 18:33
NIO, MDRX, SRNE and DVAX among midday movers
Gainers: Interpace Biosciences (IDXG) +41%.Allscripts Healthcare Solutions (MDRX) +31%.Replimune Group (REPL) +27%.VOXX International (VOXX) +25%.AnaptysBio (ANAB) +22%.NIO (NIO) +20%.OncoCyte (OCX) +20%.Panhandle Oil and Gas (PHX) +16%.RealNetworks (RNWK) +14%.Oblong (OBLG) +13%.Losers: Cyclerion Therapeutics
Seekingalpha · 10/14 16:38
Mid-Day Market Update: Crude Oil Rises 1.5%; Cyclerion Therapeutics Shares Plummet
Midway through trading Wednesday, the Dow traded up 0.01% to 28683.10 while the NASDAQ rose 0.11% to 11,876.67. The S&P also rose, gaining 0.06% to 3,514.04.
Benzinga · 10/14 16:13
Interpace Biosciences, AnaptysBio leads healthcare gainers, Cyclerion Therapeutics, Enzo Biochem among major losers
Gainers: Interpace Biosciences (IDXG) +42%, AnaptysBio (ANAB) +32%, Replimune Group (REPL) +31%, Allscripts Healthcare Solutions (MDRX) +29%, OncoCyte (OCX) +19%.Losers: Cyclerion Therapeutics (CYCN) -47%, Enzo Biochem (ENZ) -17%, Sorrento Therapeutics (SRNE) -14%, Aethlon Medical (AEMD) -14%, Celldex Therapeutics (CLDX) -8%.
Seekingalpha · 10/14 14:59
MDRX, VOXX, ENZ and FLWS among after-hours movers
Gainers: [[MDRX]] +49.2%. [[VOXX]] +18.1%. [[BBBY]] +6.2%. [[FUBO]] +5.6%. [[GME]] +5.6%.Losers: [[ENZ]] -10.7%. [[ATEC]] -9.2%. [[OCUL]] -9.2%. [[PNTG]] -6.1%. [[FLWS]] -4.7%.
Seekingalpha · 10/13 21:42
10 Stocks Moving In Tuesday's After-Hours Session
Gainers Bed Bath & Beyond (NASDAQ: BBBY) shares are trading higher after the company announced it plans to sell its non-core assets.
Benzinga · 10/13 21:21
Enzo Biochem reports FQ4 results
Enzo Biochem (ENZ): FQ4 GAAP EPS of -$0.07.Revenue of $19.5M (-6.8% Y/Y)Gross margins in the Enzo Clinical Labs division reached nearly 40% in FQ4.At the end of FY20, cash and
Seekingalpha · 10/13 20:04
Enzo Biochem Q4 EPS $(0.07) Up From $(0.11) YoY, Sales $19.50M Miss $20.92M Estimate
Enzo Biochem (NYSE:ENZ) reported quarterly losses of $(0.07) per share. This is a 36.36 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $19.50
Benzinga · 10/13 20:03
Enzo Biochem, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 13, 2020/ Enzo Biochem, Inc.
ACCESSWIRE · 10/13 19:30
If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 78%
Simply Wall St. · 09/15 14:29
Enzo Biochem doubles its capacity for molecular laboratory testing services
To meet rapidly increasing demand for its PCR-based COVID-19 molecular and serological testing, Enzo Biochem (ENZ) has expanded reagent and supply manufacturing as well as doubled its capacity for molecular
Seekingalpha · 09/08 13:19
ENZO BIOCHEM DOUBLES CAPACITY IN RESPONSE TO INCREASING DEMAND FOR COVID-19 TESTING
Facility in Farmingdale, NY, expanding manufacturing and molecular platform to support rapidly growing demand for testing services from universities, nursing homes, physician offices and urgent care facilities.NEW YORK, NY, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences
GlobeNewswire · 09/08 13:00
Webull provides a variety of real-time ENZ stock news. You can receive the latest news about Enzo Biochem through multiple platforms. This information may help you make smarter investment decisions.
About ENZ
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.
More